Abstract ： Objective ： To explore the mechanism of Jinkui Shenqi Pills (JKSQW) in treating type 2 diabetes mellitus complicated with sarcopenia in the senior. Methods： The data sets of sarcopenia and type 2 diabetes mellitus were downloaded from the Gene Expression Ommibus (GEO) database， and the intersection was taken to obtain the related targets of type 2 diabetes complicated with sarcopenia in the senior. The effective components and targets of JKSQW were screened and visualized by using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). After the intersection with the disease targets were taken，it was imported into STRING database to create the PPI network diagram and Cytoscape_v3.9.1 was used to analyze the core targets， and Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed. Finally，AutoDock Tools 1.5.6 software was used for molecular docking. Results：A total of 205 targets of JKSQW in the treatment of type 2 diabetes mellitus complicated with sarcopenia in the senior were screened out. The key components were quercetin，stigmasterol，β-sitosterol，etc.，which may be involved in the signaling pathways of diabetic complications， cell senescence， cancer， lipid， atherosclerosis，IL-17 and TNF through such core targets as interleukin (IL)6，tumor necrosis factor (TNF)， IL1 α， chemokine CCL2 ， and IL1 β. The results of molecular docking showed that stigmasterol and β- sitosterol had good binding ability with IL6 ， TNF ， CCL2 and IL1 β . Conclusion ： The possible mechanism of JKSQW in treating type 2 diabetes mellitus complicated with sarcopenia in the senior is mainly related to the IL-17 signaling pathway， while stigmasterol and β -sitosterol show good docking results with targets IL6，TNF，CCL2 and IL1β.